Vaccination against prion disease (PRIOVAX)

Objective

Based on prevention of prison disease by transgenic anti-prison protein (Prep) antibody expression in mice, we propose to develop a vaccine to actively induceati-prion immunity in mice. For this purpose, immunological self-tolerance against Prep will be analysed. On that basis recombinant virus vaccines will be developed to explore immunological intervention strategies. The consortium consists of 4 research groups conversing different fields of expertise, i.e. immunology, prison biology, antibody engineering, and recombinant virus technology. The studies will involve advanced technologies to develop new gene targeted mouse models, to establish recombinant Rhabdovirus vaccines, and to optimise anti-PrPantibodies. The results of these studies will explore the feasibility of prionvaccination in mice and will open future perspectives for developing scrapievaccines for animals and humans.

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

PAUL-EHRLICH-INSTITUT, FEDERAL AGENCY FOR SERA AND VACCINES

Address

Paul-ehrlich-strasse 51-59
63225 Langen
Germany

Participants (2)

BAXTER AG

Austria

Address

Industriestrasse 67
1220 Wien

UNIVERSITY OF ZURICH

Switzerland

Address

Scmelzbergstrasse 12
8091 Zurich